Evaluating the Efficacy and Safety of Bimekizumab for Plaque Psoriasis and Psoriatic Arthritis: An Expert Consensus Panel Report

Page 1348-1364

Iron Deficiency Anemia Pruritus: A Review with Proposed Mechanisms of Action

Page 1365-1373

Human Leukocyte Antigen DQB1 and its Implication in Scleroderma Pathogenesis: A Systematic Review

Page 1374-1383

Pitfalls in Laser-Based Device Tattoo Removal: A Literature Review

Page 1384-1395

Assessing Knowledge of Appropriate Sunscreen Guidelines and Skin Cancer Prevention Among New York Yankees Attendees

Page 1396-1398

Burnout Among Dermatology Residents and Fellows: A Survey Study

Page 1399-1404

Angiokeratoma Corporis Diffusum in the Absence of Known Metabolic Disease and Systemic Features

Page 1405-1407

More Than Meets the Eye: Localized Bullous Eruption After Transfusion

Page 1408-1412

Dupilumab-induced Acanthosis Nigricans

Page 1413-1417

Verrucous Cyst in a 7-year-old Girl

Page 1418-1422

Nevus Lipomatosus Cutaneous Superficialis: A Case Report in Egypt

Page 1423-1426

A Case of Atypical Presentation of Morpheaform Verrucous Sarcoidosis

Page 1427-1430

Progression of Atypical Fibroxanthoma to Metastatic Pleomorphic Dermal Sarcoma in a Lung Transplant Recipient

Page 1431-1434

Treatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib

Page 1435-1438

Cutaneous Ulcerations as the Presenting Sign of Acute Aortic Occlusion

Page 1439-1441

Drug-Induced Erythema Annulare Centrifugum after Dupilumab Therapy: A Case Report.

Page 1442-1445

Histopathological Granuloma Formation in a Subacute Cutaneous Lupus Erythematosus Patient

Page 1446-1450

Galli Galli Disease: A Challenging Diagnosis in a Bahraini Female Patient

Page 1451-1455

The Association Between Internet Search Patterns and Scabies Incidence Across the United States

Page 1456-1460

Retiform Plaques: An Additional Diagnostic Consideration

Page 1461-1463

A Case of Hand-Foot Skin Reaction-like Eruption Associated with Pembrolizumab

Page 1464-1467

Skeletal Muscle Regeneration – A Rare Malignancy Mimicker Encountered in Mohs Micrographic Surgery

Page 1468-1470

Coinciding Erythema Nodosum and Sweet Syndrome

Page 1471-1472

Leaping over Leprosy

Page 1473-1474

Nevus Sebaceous: A Midline Verrucous Lesion on a Neonate

Page 1475-1477

Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Individual Patient PASI and PASI-HD Responses: Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials

Page s355

Apremilast for the Treatment of Psoriasis in Special Areas in Pediatric Patients in the SPROUT Study

Page s356

Effect of Spesolimab on Achieving Sustained Disease Remission in Patients with Generalized Pustular Psoriasis: Results from the Effisayil 2 Study

Page s357

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch as Assessed by the Psoriasis Symptoms and Signs Diary

Page s358

Expected Spesolimab Plasma Exposure following Intravenous and Subcutaneous Dosing in Patients with Generalized Pustular Psoriasis

Page s359

Spesolimab Use for Generalized Pustular Psoriasis Flare Prevention in Patients with Concomitant Plaque Psoriasis: Results from the Effisayil 2 Trial

Page s360

Measuring GPPGA, Pain, Symptom, and Quality of Life Index Scores in Untreated Generalized Pustular Psoriasis: Results from the Placebo Group of the Effisayil-2 Trial

Page s361

Tapinarof Cream 1% Once Daily is Efficacious in the Treatment of Mild to Severe Plaque Psoriasis in the Head and Neck Region

Tapinarof Cream 1% Once Daily Improves Patient-Reported Outcomes in the Treatment of Mild to Severe Plaque Psoriasis in the Head and Neck Region

Deucravacitinib in Moderate Plaque Psoriasis: Efficacy in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Page s364

Deucravacitinib Long-Term Efficacy in Week 16 Placebo Crossovers: 3-year Results from the POETYK PSO Program

Page s365

Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials

Page s366

Gene Expression Differences Identified in Skin Samples of Mycosis Fungoides, Atopic Dermatitis, and Psoriasis

Page s367

Clinical Characteristics of Generalized Pustular Psoriasis Flares in the Real-World Setting

Page s368

Bimekizumab Efficacy through Year 1 in Patients with Moderate to Severe Plaque Psoriasis Who Had Not Achieved a PASI 90 Response by Week 16: A Pooled Analysis from Four Phase 3/3B Trials

Page s369

Real-World Efficacy of Spesolimab: Reports from Four Patients with Generalized Pustular Psoriasis

Page s370

Effect of High-Dose Subcutaneous Spesolimab on Skin Manifestations: Results from the Pivotal Effisayil 2 Trial of Flare Prevention in Generalized Pustular Psoriasis

Page s371

Roflumilast Cream 0.15% in Patients with Atopic Dermatitis: Individual Patient Response from the Pooled INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials

Page s372

Association Between Early Clinical Responses and Long-Term Outcomes With Ruxolitinib Cream Treatment in Mild to Moderate Atopic Dermatitis

Page s373

A Checklist to Aid in Identifying Patients with Atopic Dermatitis Who are Candidates for Systemic Therapy

Page s374

Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials

Page s375

Continuous Tralokinumab Treatment over 4 Years in Adults with Moderate-to-Severe Atopic Dermatitis Provides Long-Term Disease Control

Page s376

Progressive and Sustained Disease Control in Patients with Atopic Dermatitis (AD) Aged 12–17 Years Treated with Tralokinumab for 52 Weeks

Page s377

Factors Associated with Persistent Efficacy of Abrocitinib without Flare: A Multivariable Analysis of the JADE-REGIMEN Study

Page s378

Integrated Safety Analysis of Abrocitinib in 635 Adolescent Patients With Moderate-To-Severe Atopic Dermatitis With Over 1000 Patient-Years of Exposure

Page s379

Efficacy of Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis With Severe Itch at Baseline and in Subgroups by Baseline Thresholds of Severe Itch: A Post Hoc Analysis of the JADE COMPARE and JADE DARE Clinical Trials

Page s380

Efficacy Outcomes in Clinical Trials of Atopic Dermatitis Treatments: A Systematic Literature Review

Page s381

Early Oligoarticular Psoriatic Arthritis Responds to Treatment With Apremilast: Week 16 Results From FOREMOST - a Phase 4 Randomized Controlled Trial

Page s382

Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial

Page s383

Non-invasive Gene Expression Analysis Rules Out Melanoma with High Negative Predictive Value Regardless of Skin Phototype

Page s384

The 40-gene Expression Profile (40-GEP) Test Identifies Cutaneous Squamous Cell Carcinoma (cSCC) Patients at High Risk of Metastasis within Lower-Staged Tumors to Better Guide Treatment Decisions

Page s385

Real-World Evidence Confirms Risk Stratification of the 31-GEP and i31-GEP in Prospectively Tested Patients with Stage I-III Cutaneous Melanoma 

Page s386

Diagnostic Discordance Among Histopathological Reviewers for Difficult-to-Diagnose Melanocytic Lesions

Page s387

Efficacy Following Discontinuation of Sonidegib Treatment in Patients With Locally Advanced Basal Cell Carcinoma: Results From the BOLT 42-Month Analysis

Page s388

Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Clinical Efficacy and Application Characteristics

Page s389

Efficacy and Safety of Fixed-Dose Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne Vulgaris in Children and Adolescents

Page s390

Maintenance Acne Treatment With Topical Tazarotene after Oral Isotretinoin: Overview and Case Reports

Page s391

Efficacy and Safety of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Females with Moderate to Severe Acne: Post Hoc Analysis by Age

Page s392

Early Acne Improvements With Fixed-Dose Clindamycin Phosphate 1.2%/ Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: What to Expect in the First 4 Weeks of Treatment

Page s393

Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata

Page s394

Real-World Assessment of Disease Characteristics and Clinical Outcomes in Alopecia Areata in a Global Noninterventional Observational Cohort (ADAAGIO)

Page s395

Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II

Page s396

Clinical Efficacy and Patient Reported Impacts of Roflumilast Foam 0.3% in Seborrheic Dermatitis: An Analysis of STRATUM Data for Patients Unresponsive or Intolerant to Topical Corticosteroids

Page s397

A New Peptide Skin-Brightening Facial Cream Demonstrated Clinical Improvement in Jawline Sagging, Discoloration and Overall Photodamage

Page s398

Transungual Penetration and Antifungal Activity of Seven Prescription and Over-the-Counter Topical Antifungals: In Vitro Comparison

Page s399

Concealing Meets Healing in the Treatment of Toenail Onychomycosis: A Review of Concurrent Nail Polish Use With Topical Efinaconazole 10% Solution

Page s400

VP-102 Tolerability Evaluated by Concomitant Analgesic Medication Usage in Two Phase 3 Trials for Molluscum Contagiosum

Page s401

Roflumilast Cream 0.3% for the Treatment of Recalcitrant Lichen Nitidus

Page s402

Bimekizumab Versus Secukinumab Continuous Maintenance of PASI 90 and PASI 100 Responses through One Year in Patients with Moderate to Severe Plaque Psoriasis: Post-HOC Results from the BE RADIANT Phase 3b Trial

Page s403